Zevra Therapeutics, Inc. Stock 12‑Month Price Target Raised to $25.25, Implies 146% Upside
Zevra Therapeutics' average price target increased from $25 to $25.25 by 8 analysts, with a range of $20 to $35. This implies a 146% upside from the Oct. 30 closing price. All 9 analysts rate the stock as Buy.
How this was made
The 30-second read
Why it matters
Analyst consensus remains a Buy, reinforcing positive bias.
Market read
Target raise may prompt short‑term buying interest but limited broader market effect.
What to watch
No new clinical data disclosed; price target change may reflect broader market optimism rather than company fundamentals.
Background
Zevra Therapeutics is a micro‑cap biotech company; price target changes can move its thinly traded stock.
Ticker impact
Analysts raised the average price target for Zevra Therapeutics to $25.25, implying 146% upside.
likely upward pressure as investors price in the higher target.
Target raise is a fresh analyst action that can attract buying interest.
Market effects
May lift sentiment in the biotech/therapeutics sector.
Limited to U.S. small‑cap biotech investors.
Minimal global impact.
Counterpoint
Target raise could be premature if upcoming trial data disappoints.
Key entities
- companyZevra Therapeutics, Inc.
Biotech firm whose price target was raised.
